MPG.eBooks - Search Results - "CADTH drug reimbursement review"

Search alternatives:
"CADTH drug reimbursement review" » "CADTH drug reimbursement services", "CADTH drug reimbursement rates", "CADTH drug reimbursement rewarded", "CADTH _ reimbursement review", "CADTH cost reimbursement review", "CADTH drug reinforcement review"
cadth drug » icadts drug , catch drug

Cover Image

1

Pharmacoeconomic report: : Ranolazine (Corzyna) : (KYE pharmaceuticals) : indication: stable angina pectoris, adults

Published 2021

Canadian Agency for Drugs and Technologies in Health

“...CADTH drug reimbursement review...”

Cover Image

2

Pharmacoeconomic report: Satralizumab (Enspryng) : (Hoffmann-La Roche Limited) : indication : neuromyelitis optica spectrum disorder

Published 2021

Canadian Agency for Drugs and Technologies in Health

“...CADTH drug reimbursement review...”

Cover Image

3

Clinical review report: von Willebrand factor (recombinant) (Vonvendi) : (Shire Pharma Canada ULC, now part of Takeda Canada Inc.) : indication : for the treatment and control of b...

Published 2021

Canadian Agency for Drugs and Technologies in Health

“...CADTH drug reimbursement review...”

Cover Image

4

Pharmacoeconomic report: Dupilumab (Dupixent) (Sanofi Genzyme, a division of Sanofi-aventis Canada Inc.) : indication : indicated for the treatment of patients aged 12 years and ol...

Published 2020

Canadian Agency for Drugs and Technologies in Health

“...CADTH drug reimbursement review...”

Cover Image

5

Pharmacoeconomic report: Esketamine hydrochloride (Spravato) (Janssen inc.) : indication : major depressive disorder in adults

Published 2021

Canadian Agency for Drugs and Technologies in Health

“...CADTH drug reimbursement review...”

Cover Image

6

Clinical review report: Emicizumab (Hemlibra) : Hoffmann-La Roche Ltd. : indication: bleeding prevention, hemophilia A.

Published 2021

Canadian Agency for Drugs and Technologies in Health

“...CADTH drug reimbursement review...”

Cover Image

7

Pharmacoeconomic report: Emicizumab (Hemlibra) : Hoffman-La Roche Ltd. : indication: bleeding prevention, hemophilia A.

Published 2021

Canadian Agency for Drugs and Technologies in Health

“...CADTH drug reimbursement review...”

Cover Image

8

CADTH drug reimbursement recommendation: von Willebrand factor (Recombinant) (Vonvendi -- Takeda Canada Inc.) : indication: treatment and control of bleeding episodes in adults (ag...

Published 2021

Canadian Agency for Drugs and Technologies in Health

“...CADTH drug reimbursement review...”

Cover Image

9

Pharmacoeconomic review report: Von Willebrand factor (Recombinant) (Vonvendi) (Shire Pharma Canada ULC, now part of Takeda Canada Inc.) : indication: for the treatment and control...

Published 2021

Canadian Agency for Drugs and Technologies in Health

“...CADTH drug reimbursement review...”

Cover Image

10

Pharmacoeconomic report: Nintedanib (Ofev) Boehringer Ingelheim Canada Ltd. : indication: chronic fibrosing interstitial lung diseases

Published 2021

Canadian Agency for Drugs and Technologies in Health

“...CADTH drug reimbursement review...”

Cover Image

11

Pharmacoeconomic report: Ofatumumab (Kesimpta) (Novartis Pharmaceuticals Canada Inc.) : indication: multiple sclerosis, relapsing-remitting

Published 2021

Canadian Agency for Drugs and Technologies in Health

“...CADTH drug reimbursement review...”

Cover Image

12

Pharmacoeconomic review report: Budesonide (Jorveza) : (AVIR Pharma Inc.) : indication : for the induction of clinicopathologic remission in adults with eosinophilic esophagitis

Published 2020

Canadian Agency for Drugs and Technologies in Health

“...CADTH drug reimbursement review...”